Nanoparticles coupled with CCL2/CCR2 inhibition reduce hemorrhagic transformation in post-thrombolysis, indicating enhanced neuroprotection.
An MMP-9-responsive tPLGA nanoplatform enables spatiotemporally controlled tPA delivery for targeted thrombolysis. Coupling with CCL2/CCR2 inhibition suppresses neuroinflammation, preserves BBB integrity, and prevents hemorrhagic transformation.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: